Merial

Merial was a leading pharmaceutical company specializing in veterinary medicine and animal health products. Established in 1998 as a joint venture between Merck & Co., Inc. and Sanofi, Merial focused on developing vaccines, pharmaceuticals, and diagnostics aimed at improving the health and well-being of a wide range of animal species, including pets, livestock, and wildlife.

Throughout its years of operation, Merial was known for its innovative contributions to veterinary science. It developed notable vaccines such as those for rabies, Lyme disease, and canine parvovirus, as well as treatments for parasitic infestations and other common animal health issues. The company maintained a global presence, with subsidiaries and research facilities across North America, Europe, and Asia.

In 2017, Merial was acquired by Boehringer Ingelheim, a German pharmaceutical company, in a strategic move to expand its animal health segment. Following the acquisition, Merial’s products and expertise were integrated into Boehringer Ingelheim’s broader animal health portfolio, continuing to influence veterinary medicine.

Merial played a significant role in advancing animal health through research, innovation, and collaboration with veterinary professionals. Its efforts contributed to improvements in disease prevention, treatment, and overall animal welfare. The company's legacy persists through its contributions to the field and the ongoing availability of many of its products under the Boehringer Ingelheim brand.

As of recent years, the Merial brand has been gradually phased out, with its operations absorbed into Boehringer Ingelheim’s global structure, reflecting industry trends toward consolidation to enhance research and development capabilities in animal health.